Literature DB >> 28785785

Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma.

Michael L Wells1, David M Hough1, Jeff L Fidler1, Patrick S Kamath2, Joseph T Poterucha3, Sudhakar K Venkatesh4.   

Abstract

PURPOSE: To describe the imaging appearance of hyperenhancing nodules arising in post-Fontan patients and to identify specific features best correlated with malignancy.
METHODS: Hyperenhancing hepatic nodules visible on CT and/or MRI in post-Fontan patients were identified retrospectively and reviewed by subspecialty radiologists. Nodules with characteristic imaging findings of focal nodular hyperplasia (FNH) were defined as typical, the remainder were defined as atypical, described in detail according to LIRADS criteria, and length of stability over time was recorded. Clinical data, alpha fetoprotein levels (AFP), central venous pressures (CVP), and histopathology were recorded.
RESULTS: 245 hyperenhancing nodules (215 typical, 30 atypical) were evaluated in 30 patients. Twenty-nine atypical nodules showed washout (portal phase in 6, delayed phase in 29), 0 showed pseudocapsule, 1 showed threshold growth, 1 showed tumor in vein, and 5 showed ancillary features favoring malignancy. Pathology confirmed hepatocellular carcinoma (HCC) in 3 atypical nodules and FNH-like histology in 3 atypical and 4 typical nodules. 2 atypical nodules were present in a patient with clinical diagnosis of HCC. 20 nodules (7 typical, 13 atypical due to washout) were studied with hepatobiliary contrast agent and all showed homogenous hepatobiliary phase retention. Atypical nodules were significantly more likely to be HCC than biopsy-proven FNH-like or stable ≥24 months when showing portal phase washout (P < 0.001), mosaic architecture (P = 0.020) or in the presence of cirrhosis (P = 0.004) or elevated AFP (P = 0.004). Atypical nodules that were HCC had higher median CVP than those that were FNH-like (19, range 16-27 vs. 13, range 12-16 mmHg, P = 0.0003), there was not a significant difference based on median patient age (HCC 30, range 10-41 vs. FNH-like 40 range 10-41, P = 0.244).
CONCLUSIONS: Benign hyperenhancing masses in Fontan patients may demonstrate washout and be mistaken for HCC by imaging criteria. Portal phase washout, mosaic architecture, elevated AFP and higher CVP were associated with HCC in the atypical nodules found in this population.

Entities:  

Keywords:  Congestive hepatopathy; Focal nodular hyperplasia; Fontan; Heart failure; Hepatocellular carcinoma; Washout

Mesh:

Substances:

Year:  2017        PMID: 28785785     DOI: 10.1007/s00261-017-1181-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  14 in total

1.  Assessing hepatic impairment in Fontan-associated liver disease using the HepQuant SHUNT test.

Authors:  Alexander Lemmer; Lisa VanWagner; Zaira Gasanova; Steve Helmke; Gregory T Everson; Daniel Ganger
Journal:  Congenit Heart Dis       Date:  2019-08-01       Impact factor: 2.007

Review 2.  Congenital Heart Disease and the Liver.

Authors:  Moira B Hilscher; Patrick S Kamath
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-11-06

3.  Hepatocyte-specific contrast-enhanced MRI findings of focal nodular hyperplasia-like nodules in the liver following chemotherapy in pediatric cancer patients.

Authors:  H Nursun Özcan; Muşturay Karçaaltıncaba; Turgut Seber; Bilgehan Yalçın; Berna Oğuz; Canan Akyüz; Mithat Haliloğlu
Journal:  Diagn Interv Radiol       Date:  2020-07       Impact factor: 2.630

Review 4.  Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy.

Authors:  Alexander Lemmer; Lisa B VanWagner; Daniel Ganger
Journal:  Hepatology       Date:  2018-09-22       Impact factor: 17.425

Review 5.  Screening modalities for the diagnosis of Fontan-associated liver disease: evidence from the past for future development.

Authors:  Saviga Sethasathien; Krit Leemasawat; Suchaya Silvilairat; Rekwan Sittiwangkul; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

6.  Benign Hepatic Nodules Mimicking Hepatocellular Carcinoma in the Setting of Fontan-associated Liver Disease: A Case Report.

Authors:  Anıl Çolaklar; Stephen J Lehnert; Temel Tirkes
Journal:  Euroasian J Hepatogastroenterol       Date:  2020 Jan-Jun

7.  Biomarker profile in stable Fontan patients.

Authors:  Anita Saraf; Christine De Staercke; Ian Everitt; Alice Haouzi; Yi-An Ko; Staci Jennings; Jonathan H Kim; Fred H Rodriguez; Andreas P Kalogeropoulos; Arshed Quyyumi; Wendy Book
Journal:  Int J Cardiol       Date:  2020-01-09       Impact factor: 4.164

Review 8.  From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?

Authors:  Anna Sessa; Manon Allaire; Pascal Lebray; Mourad Medmoun; Alberto Tiritilli; Pierre Iaria; Jean-François Cadranel
Journal:  JHEP Rep       Date:  2021-01-27

Review 9.  Abdominal imaging findings in adult patients with Fontan circulation.

Authors:  Tae-Hyung Kim; Hyun Kyung Yang; Hyun-Jung Jang; Shi-Joon Yoo; Korosh Khalili; Tae Kyoung Kim
Journal:  Insights Imaging       Date:  2018-04-05

10.  Repeated TACE in HCC after Fontan surgery and situs viscerum inversus: A case report.

Authors:  Fulvio Gasparrini; Ilaria Lenci; Maria Giulia Gagliardi; Marco Spada; Fabio Salimei; Antonio Orlacchio
Journal:  Radiol Case Rep       Date:  2021-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.